XmAb143 / Xencor - LARVOL DELTA

XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP (SITC 2022) - "Conversely, XmAb143 pharmacodynamics in cynomolgus monkey pilot tox studies was observed only at higher doses, and serum half-life improved from hours to days over WT IL18-Fc. Conclusions XmAb143, our engineered monovalent IL18-Fc fusion demonstrates insensitivity to IL18BP inhibition, robust inflammation activity in vivo, and improved pharmacokinetics in mice and cynomolgus monkeys."

Oncology • IFNG • IL15 • IL18BP • PD-L1

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting (Businesswire) - "Xencor, Inc... today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Boston, November 10-12, 2022....Data from the first patients enrolled in a Phase 2 study of vudalimab, Xencor’s selective PD-1 x CTLA-4 bispecific antibody, plus chemotherapy in patients with metastatic castration-resistant prostate cancer, will be presented in abstract 668."

P1 data • P2 data • Preclinical • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

Engineered IL18 heterodimeric Fc-fusions featuring improved stability, reduced potency, and insensitivity to IL18BP (AACR 2022) - "Analysis of serum from the study revealed up to 100-fold increases in IFNγ levels. Our engineered, reduced-potency IL18-Fc cytokines demonstrate robust inflammation activity in vivo, improved pharmacokinetics in mice, and insensitivity to IL18BP inhibition."

IO biomarker • Oncology • IFNG • IL15 • IL18BP • PD-L1

Xencor to Present Preclinical Data from XmAb Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Businesswire) - "Xencor...today announced it will present preclinical data on two novel XmAb® cytokine programs...'We look forward to sharing our first preclinical data from two additional wholly owned cytokine programs, a decoy-resistant and potency-reduced IL18-Fc fusion protein, and a LAG-3 targeted IL15/IL15α-Fc fusion protein, which is biased toward binding and activating checkpoint-upregulated lymphocytes that are more likely to be tumor-reactive.'"

Preclinical • Oncology